Consensus Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 20:00:00 16/03/2026 GMT			5-day change	1st Jan Change
16.18 ^USD	+0.34%		+2.89%	-7.52%

03-11	Summit Therapeutics Inc. Presents at The Citizens Life Sciences Conference 2026, Mar-11-2026 02:15 PM
03-02	Summit Therapeutics Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-02-2026 02:30 PM

Evolution of the Average Target: Summit Therapeutics Inc.

Evolution of the Target Price: Summit Therapeutics Inc.

Changes in Analyst Recommendations: Summit Therapeutics Inc.

e79.Ql2b8wMFVz78D-BcvxVk-kobEBZ96WUYkphauayJ5To.GyTal0ZPGG-aRros9XctnXooICZJnAZ7p8FtzsLFgk4YHM_GQmI0SJtIiw~c91aebd13ce839ba3ceca55b4c14be5a

Analysts' recommendations: Summit Therapeutics Inc.

12-17	Barclays Upgrades Summit Therapeutics to Equal Weight From Underweight, Adjusts Price Target to $18 From $16	MT
21/10/25	Analyst recommendations: Apple, Rivian, Goldman Sachs, Lyft, Morgan Stanley…
20/10/25	Summit Therapeutics Inc. Plans to Submit a BLA in Fourth Quarter 2025 for Ivonescimab Based on Harmoni Global Phase III Study Results	CI
17/09/25	Barclays Initiates Summit Therapeutics at Underweight With $13 Price Target	MT
04/09/25	Guggenheim Initiates Summit Therapeutics at Buy With $40 Price Target	MT
19/08/25	Piper Sandler Initiates Summit Therapeutics at Neutral With $21 Price Target	MT
13/08/25	Summit Therapeutics Pullback Seen as 'Overreaction' Amid Liquidity Options, Truist Says	MT
01/07/25	UBS Initiates Summit Therapeutics at Buy With $30 Price Target	MT
11/06/25	Leerink Partners Initiates Coverage on Summit Therapeutics With Underperform Rating, $12 Price Target	MT
08/05/25	TD Cowen Initiates Summit Therapeutics at Buy	MT
25/04/25	Top Midday Decliners	MT
26/03/25	Citigroup Upgrades Summit Therapeutics to Buy From Neutral, Adjusts Price Target to $35 From $23	MT
21/03/25	Cantor Fitzgerald Initiates Summit Therapeutics at Overweight	MT
12/03/25	Evercore ISI Initiates Summit Therapeutics at Outperform With $30 Price Target	MT
28/02/25	Goldman Sachs Initiates Summit Therapeutics at Buy With $42 Price Target	MT
08/01/25	Truist Initiates Summit Therapeutics at Buy With $35 Price Target	MT
11/12/24	Wells Fargo Initiates Summit Therapeutics at Overweight With $30 Price Target	MT
06/12/24	Jefferies Initiates Summit Therapeutics at Buy With $31 Price Target	MT
04/11/24	JMP Securities Initiates Summit Therapeutics at Market Outperform With $32 Price Target	MT
27/09/24	Citigroup Downgrades Summit Therapeutics to Neutral From Buy, Adjusts Price Target to $23 From $19	MT
03/06/24	Stifel Adjusts Summit Therapeutics Price Target to $14 From $8, Maintains Buy Rating	MT
07/05/24	Citigroup Starts Summit Therapeutics With Buy Rating, $7 Price Target	MT
26/03/24	Stifel Initiates Summit Therapeutics With Buy Rating, $8 Price Target	MT
18/11/20	SUMMIT THERAPEUTICS : HC Wainwright Downgrades Summit Therapeutics to Neutral from Buy	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	SUMMIT THERAPEUTICS INC.					+94.72%
	ARGENX SE					+37.03%
	WUXI APPTEC CO., LTD.					+46.5%
	INSMED INCORPORATED					+52.69%
	BIONTECH SE					+42.05%
	WUXI BIOLOGICS (CAYMAN) INC.					+30.59%
	GENMAB A/S					+30.97%
	AKESO, INC.					+58.36%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+36%
	EXELIXIS, INC.					+13.56%
	Average					+44.25%
	Weighted average by Cap.					+43.83%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.18GBP

Average target price

21.97GBP

Spread / Average Target

+80.41%

High Price Target

30.36GBP

Spread / Highest target

+149.34%

Low Price Target

8.887GBP

Spread / Lowest Target

-27.02%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Barclays
Guggenheim
Piper Sandler
UBS
Leerink Partners
TD Cowen
Citigroup
Cantor Fitzgerald
Evercore ISI
Goldman Sachs
Truist Securities
Wells Fargo Securities
Jefferies & Co.
JMP Securities
Stifel Nicolaus